Antiallergic properties of lemon quince.
Article Type: Report
Subject: Asthma (Care and treatment)
Allergic reaction (Care and treatment)
Allergy (Care and treatment)
Medicinal plants (Usage)
Medicinal plants (Health aspects)
Lemon (Health aspects)
Author: Finney-Brown, Tessa
Pub Date: 09/22/2011
Publication: Name: Australian Journal of Medical Herbalism Publisher: National Herbalists Association of Australia Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2011 National Herbalists Association of Australia ISSN: 1033-8330
Issue: Date: Fall, 2011 Source Volume: 23 Source Issue: 3
Product: Product Code: 0139913 Medicinal Plants; 0174012 Lemons NAICS Code: 1119 Other Crop Farming; 11132 Citrus (except Orange) Groves SIC Code: 2833 Medicinals and botanicals; 0174 Citrus fruits
Geographic: Geographic Code: 4E Europe
Accession Number: 271323820
Full Text: Grundemann C, Papagiannopoulos M, Lamy E, Mersch-Sundermann V, Huber R. 2011. Immunomodulatory properties of a lemon-quince preparation (Gencydo[R]) as an indicator of antiallergic potency. Phytomed 18;760-8.

In the Western world there has been a rise in the rates of allergic diseases over the past few decades, particularly rhinitis and asthma. In part the initiation of allergic reactions (both early and late phase) is due to the release of soluble mediators of inflammation from basophils, mast cells and nose and lung epithelial cells. In Europe around 30% of patients with allergic conditions use complementary therapies to manage them, mostly in order to avoid side effects.

One of the more commonly used products is Gencydo[R], an aqueous quince extract (Cydonia oblonga fructus 1:2.1) combined with lemon juice (Citrus limon succus). This is based on a traditional medicine used in the area for centuries. In past trials this product has shown positive outcomes on grass pollen allergy and seasonal allergic rhinitis.

The aim of the present study was to analyse the effects of complementary medicine on the release of soluble mediators from basophilic cells, mast cells and lung epithelial cells in attempts to further clarify the mechanisms of action. Both human and murine cell lines were used to assess the effects on different body tissues.

Results demonstrated a Gencydo[R] induced inhibition of the release of soluble mediators from basophilic cells, mast cells and lung epithelial cells. In some areas the effects elicited were comparable to those of a number of pharmaceutical preparations used in treating asthma and allergic rhinitis including azelastine and dexamethasone. In addition to inhibition of degranulation of basophils and mast cells, Gencydo[R] inhibited IgE mediated release of GM-CSF, a cytokine that promotes eosinophil activation and survival which may contribute to airway inflammation in asthma.

This data on mode of action suggests that Gencydo[R] may affect chronic allergic disorders beneficially via the inhibition of inflammatory and allergic mediatior release.

Tessa Finney-Brown MNHAA
Gale Copyright: Copyright 2011 Gale, Cengage Learning. All rights reserved.